Technical Analysis for AQST - Aquestive Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 6.32% | |
| Down 3 Days in a Row | Weakness | 6.32% | |
| Gapped Down | Weakness | 6.32% | |
| Lower Bollinger Band Touch | Weakness | 6.32% | |
| Calm After Storm | Range Contraction | -2.96% | |
| Wide Bands | Range Expansion | -2.96% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -6.28% | |
| Calm After Storm | Range Contraction | -6.28% | |
| NR7 | Range Contraction | -6.28% | |
| Lower Bollinger Band Walk | Weakness | -6.28% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 12 minutes ago |
| Up 5% | 12 minutes ago |
| Up 3% | 27 minutes ago |
| Up 2% | 42 minutes ago |
| Up 1% | about 1 hour ago |
Get a Trading Sidekick!
- Earnings date: 06/20/2024
Aquestive Therapeutics, Inc. Description
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Disease Drugs Psychoactive Drugs Opioids Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Seizure Gabaa Receptor Positive Allosteric Modulators Neuroendocrine Tumors Neuroendocrine Tumor Parkinson’s Disease Anaphylaxis Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.23 |
| 52 Week Low | 1.2514 |
| Average Volume | 3,205,620 |
| 200-Day Moving Average | 2.54 |
| 50-Day Moving Average | 4.25 |
| 20-Day Moving Average | 3.81 |
| 10-Day Moving Average | 3.52 |
| Average True Range | 0.37 |
| RSI (14) | 35.06 |
| ADX | 19.3 |
| +DI | 17.20 |
| -DI | 31.55 |
| Chandelier Exit (Long, 3 ATRs) | 3.45 |
| Chandelier Exit (Short, 3 ATRs) | 4.01 |
| Upper Bollinger Bands | 4.57 |
| Lower Bollinger Band | 3.04 |
| Percent B (%b) | 0.03 |
| BandWidth | 40.00 |
| MACD Line | -0.23 |
| MACD Signal Line | -0.16 |
| MACD Histogram | -0.0737 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.57 | ||||
| Resistance 3 (R3) | 3.56 | 3.40 | 3.49 | ||
| Resistance 2 (R2) | 3.40 | 3.27 | 3.40 | 3.46 | |
| Resistance 1 (R1) | 3.24 | 3.20 | 3.16 | 3.25 | 3.43 |
| Pivot Point | 3.08 | 3.08 | 3.03 | 3.08 | 3.08 |
| Support 1 (S1) | 2.92 | 2.95 | 2.84 | 2.93 | 2.74 |
| Support 2 (S2) | 2.76 | 2.88 | 2.76 | 2.71 | |
| Support 3 (S3) | 2.60 | 2.76 | 2.69 | ||
| Support 4 (S4) | 2.61 |
